Effects of asthma and asthma therapies on bone mineral density

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 1, 2002, Pages 39-44

  Wong, C A ^a   Subakumar, G ^a   Casey, P M ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ASTHMA; BONE ATROPHY; BONE DENSITY; CORTICOSTEROID THERAPY; DRUG SAFETY; FRACTURE; HUMAN; REVIEW; RISK FACTOR;

EID: 0036134941     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200201000-00007     Document Type: Review

References (92)

1. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
2. Treatment of post menopausal osteoporosis
3. The contributions of growth and puberty to peak bone mass
4. Assessment of work performance in asthma for determination of cardiorespiratory fitness and training capacity
5. Effect of asthma on growth and puberty
6. Asthma, inhaled corticosteroid treatment, and growth
7. Effect of asthma and its treatment on growth: Four year follow up of cohort of children from general practices in Tayside, Scotland
8. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma
9. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate
10. Bone mineral density in normal and asthmatic children
11. Bone mineral density in perimenopausal women with asthma: A population-based cross-sectional study
12. Glucocorticoid-induced osteoporosis: Pathogenesis and management
13. Glucocorticoids and osteoporosis
14. Pathogenesis and treatment of steroid osteoporosis
15. A model of lifetime osteoporosis impact
16. The direct medical costs of osteoporosis for American women aged 45 and older
17. Efficacy and safety of inhaled corticosteroids
18. Urinary galactosyl-hydroxylysine in postmenopausal osteoporotic women: A potential marker of bone fragility
19. Bone biomarkers as tools in osteoporosis management
20. Bone mass measurement: Prediction of risk
21. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
22. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study
23. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study
24. Steroid-induced fractures and bone loss in patients with asthma
25. Rheumatoid arthritis, corticosteroid therapy and hip fracture
26. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Effect of low dose corticosteroids
27. Hip fractures attributable to corticosteroids use
28. Vertebral fracture risk with long-term corticosteroid therapy: Prevalence and relation to age, bone density and corticosteroid use
29. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease
30. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease
31. Vertebral osteoporosis in rheumatoid arthritis patients: Effect of low dose prednisone therapy
32. Corticosteroid-induced bone loss: A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography
33. Corticosteroids and bone mass in asthma: Comparison with rheumatoid arthritis and polymyalgia rheumatica
34. Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids
35. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients
36. Osteoporosis in steroid-dependent asthma
37. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids
38. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitrol and calcitonin
39. Corticosteroid effects on proximal femur bone loss
40. Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy
41. A UK consensus group on management of glucocorticoid-induced osteoporosis: An update
42. Effect of inhaled corticosteroids on bones and growth
43. Inhaled corticosteroids, bone formation and osteocalcin
44. Beclomethasone inhalation decreases serum osteocalcin concentrations
45. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction
46. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction
47. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study
48. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects
49. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial
50. Effect of inhaled corticosteroid on bone density in asthmatic patients: A pilot study
51. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids
52. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism
53. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate
54. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids
55. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma
56. Inhaled and oral corticosteroids: Their effects on bone mineral density in older adults
57. Bone density in asthmatic patients taking inhaled corticosteroids: Comparison of budesonide and beclomethasone diproprionate
58. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma
59. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: A case-control study
60. Influence of inhaled corticosteroids and dietary intake on bone density and metabolism in patients with moderate to severe asthma
61. Bone mineral density and body composition in patients with airflow obstruction: The role of inhaled steroid therapy, disease and lifestyle
62. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density
63. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years
64. Long-term influence of inhaled corticosteroids on bone metabolism and density
65. Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: A randomised parallel group study in adult asthmatic subjects
66. Inhaled corticosteroid use and bone-mineral density in patients with asthma
67. Effect of beclomethasone dipropionate on bone mineral content assessed by x-ray densitometry in asthmatic children: A longitudinal evaluation
68. Cross-sectional study of bone density in asthmatic children
69. Effect on cortical and trabecular bone mass of different anti-inflammatory treatments in preadolescent children with chronic asthma
70. Longitudinal assessment of bone mineral density in children with chronic asthma
71. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: Comparison of fluticasone propionate with beclomethasone dipropionate
72. Bone mineral density and bone metabolism of prepubertal children with asthma after long term treatment with inhaled corticosteroids
73. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide
74. Longitudinal evaluation of bone mass in asthmatic children treated with inhaled beclomethasone dipropionate or cromolyn sodium
75. Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma
76. Bone density in asthmatic children treated with inhaled corticosteroids
77. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
78. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
79. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years
80. Extrapulmonary effects of maintenance therapy with theophylline and inhaled albuterol in patients with chronic asthma
81. Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma
82. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children
83. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission
84. Vertebral bone mineral density changes in female rheumatoid arthritis patients treated with low-dose methotrexate
85. Bone mass change during methotrexate treatment in patients with juvenile rheumatoid arthritis
86. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis
87. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine
88. Azathioprine alone is bone sparing and does not alter cyclosporine A-induced osteopenia in the rat
89. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
90. The deleterious effects of long-term cyclosporin A, cyclosporin G and FK 506 on bone mineral metabolism in vivo
91. Bone loss after renal transplantation: Role of hyperparathyroidism, acidosis, cyclosporine and systemic disease